JPH11511968A - 抗原提示細胞上にて抗原密度を増加させる方法 - Google Patents
抗原提示細胞上にて抗原密度を増加させる方法Info
- Publication number
- JPH11511968A JPH11511968A JP9509560A JP50956097A JPH11511968A JP H11511968 A JPH11511968 A JP H11511968A JP 9509560 A JP9509560 A JP 9509560A JP 50956097 A JP50956097 A JP 50956097A JP H11511968 A JPH11511968 A JP H11511968A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mhc class
- pathway
- tap
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 89
- 239000000427 antigen Substances 0.000 title claims abstract description 42
- 108091007433 antigens Proteins 0.000 title claims abstract description 42
- 102000036639 antigens Human genes 0.000 title claims abstract description 42
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 37
- 230000001965 increasing effect Effects 0.000 title description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 386
- 108091054437 MHC class I family Proteins 0.000 claims abstract description 106
- 102000043129 MHC class I family Human genes 0.000 claims abstract description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 89
- 230000037361 pathway Effects 0.000 claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 229940079156 Proteasome inhibitor Drugs 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 19
- 239000003207 proteasome inhibitor Substances 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 244000052769 pathogen Species 0.000 claims abstract description 10
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 73
- 108091034117 Oligonucleotide Proteins 0.000 claims description 68
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 67
- 210000004988 splenocyte Anatomy 0.000 claims description 48
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 108020004999 messenger RNA Proteins 0.000 claims description 21
- 230000001464 adherent effect Effects 0.000 claims description 20
- 230000000692 anti-sense effect Effects 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 17
- 210000004443 dendritic cell Anatomy 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 17
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 13
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 10
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 8
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 claims description 7
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 7
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 5
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 5
- 108010004877 CEP 1612 Proteins 0.000 claims description 4
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 4
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 4
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 4
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 4
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108010081055 CEP 1508 Proteins 0.000 claims description 3
- 108010080997 CEP 1513 Proteins 0.000 claims description 3
- 108090001102 Hammerhead ribozyme Proteins 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 208000008732 thymoma Diseases 0.000 claims description 3
- 108010004658 CEP 1601 Proteins 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 101100082486 Arabidopsis thaliana CEP6 gene Proteins 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 abstract description 15
- 238000001727 in vivo Methods 0.000 abstract description 14
- 230000003389 potentiating effect Effects 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 description 48
- 108010058846 Ovalbumin Proteins 0.000 description 47
- 102000054766 genetic haplotypes Human genes 0.000 description 39
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 29
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 28
- 102000011931 Nucleoproteins Human genes 0.000 description 21
- 108010061100 Nucleoproteins Proteins 0.000 description 21
- 238000011282 treatment Methods 0.000 description 19
- 108010078791 Carrier Proteins Proteins 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 241000711549 Hepacivirus C Species 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 10
- 230000030741 antigen processing and presentation Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 201000002674 obstructive nephropathy Diseases 0.000 description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 229940092253 ovalbumin Drugs 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 229940054269 sodium pyruvate Drugs 0.000 description 5
- 239000000021 stimulant Substances 0.000 description 5
- -1 CEP690 Proteins 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229910052693 Europium Inorganic materials 0.000 description 3
- 101000652570 Homo sapiens Antigen peptide transporter 1 Proteins 0.000 description 3
- 241001553014 Myrsine salicina Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000057131 human TAP1 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101150055806 AS gene Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100045395 Mus musculus Tap1 gene Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000824644 Otites Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0648—Splenocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.細胞に接触させたペプチドの提示を変更するために、細胞のペプチドへの 接触前に細胞中のMHCクラスI経路関連成分の活性を阻害することからなる方 法。 2.MHCクラスI経路関連成分がTAP蛋白質である、請求項1記載の方法 。 3.MHCクラスI経路関連成分がLMP蛋白質である、請求項1記載の方法 。 4.LMP蛋白質がLMP2およびLMP7からなる群から選択される、請求 項3記載の方法。 5.MHCクラスI経路関連成分が熱ショック蛋白質である、請求項1記載の 方法。 6.熱ショック蛋白質がgp96、HSP90およびHSP70からなる群か ら選択される、請求項5記載の方法。 7.MHCクラスI経路関連成分がプロテオゾームである、請求項1記載の方 法。 8.プロテオゾームが26Sプロテオゾームである、請求項7記載の方法。 9.プロテオゾームが20Sプロテオゾームである、請求項7記載の方法。 10.請求項1記載の方法により生成された細胞。 11.MHCクラスI経路関連蛋白質の発現を減じるアンチセンスオリゴヌク レオチドを含む細胞。 12.MHCクラスI経路関連蛋白質の発現を減じるアンチセンス遺伝子を含 む細胞。 13.阻害が、MHCクラスI経路関連蛋白質をコードするmRNAのすべて または一部に相補なアンチセンスオリゴヌクレオチドを細胞に導入することによ りMHCクラスI経路関連蛋白質の翻訳を阻害することからなる、請求項1記載 の方法。 14.阻害が、MHCクラスI経路関連蛋白質をコードするmRNAのすべて または一部に相補なRNAをコードするアンチセンス遺伝子を細胞に導入するこ とによりMHCクラスI経路関連蛋白質の翻訳を阻害することからなる、請求項 1記載の方法。 15.病原体に感染した哺乳類に細胞を投与することをさらに含む、請求項1 記載の方法。 16.請求項10記載の細胞および薬学上受容可能な賦形剤を含むワクチン。 17.TAPがTAP−1である、請求項2記載の方法。 18.TAPがTAP−2である、請求項2記載の方法。 19.細胞がTリンパ球である、請求項1記載の方法。 20.細胞がRMA細胞である、請求項1記載の方法。 21.細胞が粘着性または非粘着性スプレノサイトである、請求項1記載の方 法。 22.細胞が粘着性または非粘着性末梢血単核細胞である、請求項1記載の方 法。 23.細胞が樹状細胞である、請求項1記載の方法。 24.細胞がマクロファージである、請求項1記載の方法。 25.細胞が胸腺腫の細胞である、請求項1記載の方法。 26.アンチセンスオリゴヌクレオチドが25から30ヌクレオチドの長さで あって配列: 5’AGGGCCTCAGGTAGGACAGCGCCAT3’(配列番号1) を含む、請求項13記載の方法。 27.アンチセンスオリゴヌクレオチドが25から30ヌクレオチドの長さで あって配列: 5.GCAGCAGGATATTGGCATTGAAAGG3’(配列番号2) を含む、請求項13記載の方法。 28.ペプチドが病原体により天然に発現される蛋白質の一部からなる6から 15のアミノ酸のポリペプチドである、請求項1記載の方法。 29.細胞がBリンパ球である、請求項1球の方法。 30.ペプチドが腫瘍特異性抗原である、請求項1記載の方法。 31.阻害が、MHCクラスI経路関連蛋白質に結合して該蛋白質の機能を阻 害するあとりのRNAを細胞に導入することからなる、請求項1記載の方法。 32.MHCクラスI経路関連蛋白質がTAP蛋白質およびLMP蛋白質から なる群から選択される、請求項31記載の方法。 33.阻害が、MHCクラスI経路関連蛋白質をコードするmRNAを特異的 に分断するリボザイムを細胞に導入してそれによりMHCクラスI経路関連蛋白 質の翻訳を阻害することからなる、請求項1記載の方法。 34.リボザイムがハンマーヘッドリボザイムである、請求項33記載の方法 。 35.MHCクラスI経路関連成分がTAP蛋白質およびLMP蛋白質からな る群から選択される、請求項33記載の方法。 36.阻害が、細胞をプロテアゾーム阻害剤に接触させることからなる、請求 項1記載の方法。 37.プロテアゾーム阻害剤がLLnL,MG115,MG132,CEP6 90,CEP1508,CEP1513,CEP1612,およびラクタシスチ ンからなる群から選択される、請求項36記載の方法。 38.プロテアゾーム阻害剤がMG132である、請求項37記載の方法。 39.細胞中のMHCクラスI経路関連成分の活性を阻害し、 細胞を腫瘍特異的抗原に接触させてそれにより抗原提示細胞を生成し、 そして 抗原提示細胞を哺乳類に投与すること からなる、哺乳類の癌の処置または予防方法。 40.MHCクラスI経路関連成分がTAPである、請求項39記載の方法。 41.MHCクラスI経路関連成分がLAPである、請求項39記載の方法。 42.MHCクラスI経路関連成分がプロテアゾームである、請求項39記載 の方法。 43.請求項10記載の細胞をTリンパ球に接触させることからなる、Tリン パ球のインビトロ増殖を刺激する方法。 44.細胞中のMHCクラスI経路関連成分の活性を阻害し、 細胞を腫瘍特異的抗原に接触させてそれにより抗原提示細胞を生成し、 そして 抗原提示細胞をTリンパ球に接触させることにより細胞毒性Tリンパ球 を生成すること により生成された細胞毒性Tリンパ球。 45.MHCクラスI経路関連成分がTAPである、請求項44記載の方法。 46.MHCクラスI経路関連成分がLAPである、請求項44記載の方法。 47.MHCクラスI経路関連成分がプロテアゾームである、請求項44記載 の方法。 48.請求項44記載の細胞毒性Tリンパ球を哺乳類に投与することからなる 、病原体に感染した哺乳類を処置する方法。 49.請求項44記載の細胞毒性Tリンパ球を哺乳類に投与することからなる 、哺乳類の癌を処置する方法。 50.プロテアゾーム阻害剤がCEP1601である、請求項36記載の方法 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51737395A | 1995-08-21 | 1995-08-21 | |
US08/517,373 | 1995-08-21 | ||
PCT/US1996/013457 WO1997007128A1 (en) | 1995-08-21 | 1996-08-20 | A method to increase the density of antigen on antigen presenting cells |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11511968A true JPH11511968A (ja) | 1999-10-19 |
Family
ID=24059549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9509560A Ceased JPH11511968A (ja) | 1995-08-21 | 1996-08-20 | 抗原提示細胞上にて抗原密度を増加させる方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5831068A (ja) |
EP (1) | EP0863913A4 (ja) |
JP (1) | JPH11511968A (ja) |
AU (1) | AU7008896A (ja) |
CA (1) | CA2230195A1 (ja) |
WO (1) | WO1997007128A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
SE9604581D0 (sv) * | 1996-12-12 | 1996-12-12 | Karolinska Innovations Ab | An agent against cancer and virus infections |
US6228640B1 (en) | 1997-02-07 | 2001-05-08 | Cem Cezayirli | Programmable antigen presenting cell of CD34 lineage |
US6977073B1 (en) | 1997-02-07 | 2005-12-20 | Cem Cezayirli | Method for stimulating an immune response |
US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
US6133308A (en) * | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
WO1999009006A1 (en) * | 1997-08-15 | 1999-02-25 | Soucy Francois | SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF |
JP2002507392A (ja) * | 1998-02-11 | 2002-03-12 | マキシジェン, インコーポレイテッド | 遺伝子ワクチンの免疫調節特性の最適化 |
EP1518927A3 (en) * | 1998-02-11 | 2005-06-22 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
AU755156B2 (en) * | 1998-03-20 | 2002-12-05 | Genzyme Corporation | Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby |
US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
GB9817693D0 (en) * | 1998-08-14 | 1998-10-07 | Bridgehead Technologies Limite | Virally-mediated targeting of drugs and genetic material |
WO2000047230A1 (fr) * | 1999-02-10 | 2000-08-17 | The Kitasato Institute | Potentialisateurs d'agent anticancereux |
WO2000075365A2 (en) * | 1999-06-08 | 2000-12-14 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
US7122335B1 (en) * | 1999-06-08 | 2006-10-17 | University Of Iowa Research Foundation | Compounds and methods to enhance rAAV transduction |
AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
US6649593B1 (en) * | 1999-10-13 | 2003-11-18 | Tularik Inc. | Modulators of SREBP processing |
EP1608763A2 (en) * | 2003-03-31 | 2005-12-28 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
US20070281336A1 (en) * | 2006-04-14 | 2007-12-06 | Epicentre Technologies | Kits and methods for generating 5' capped RNA |
US20090017062A1 (en) * | 2006-04-28 | 2009-01-15 | Iowa Research Foundation Iowa Centers For Enterpri | Methods and compounds to alter virus infection |
MX2008015395A (es) | 2006-08-18 | 2008-12-15 | Argos Therapeutics Inc | Uso de cd83 en terapias de combinacion. |
EP2557089A2 (en) | 2011-07-15 | 2013-02-13 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compositions and methods for immunomodulation |
WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
MX2018010842A (es) | 2016-03-07 | 2019-07-04 | Univ Iowa Res Found | Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2089488A1 (en) * | 1990-09-06 | 1993-03-07 | Judy Lieberman | Pathogen-specific ctl therapy |
CA2168950A1 (en) * | 1993-08-06 | 1995-02-16 | Esteban Celis | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl |
JPH09504168A (ja) * | 1993-09-03 | 1997-04-28 | チロン ビアジーン,インコーポレイティド | 遺伝子療法によって免疫応答を抑制する方法 |
-
1996
- 1996-08-20 WO PCT/US1996/013457 patent/WO1997007128A1/en active Application Filing
- 1996-08-20 US US08/700,035 patent/US5831068A/en not_active Expired - Fee Related
- 1996-08-20 JP JP9509560A patent/JPH11511968A/ja not_active Ceased
- 1996-08-20 CA CA002230195A patent/CA2230195A1/en not_active Abandoned
- 1996-08-20 AU AU70088/96A patent/AU7008896A/en not_active Abandoned
- 1996-08-20 EP EP96931395A patent/EP0863913A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2230195A1 (en) | 1997-02-27 |
US5831068A (en) | 1998-11-03 |
EP0863913A1 (en) | 1998-09-16 |
AU7008896A (en) | 1997-03-12 |
EP0863913A4 (en) | 2001-04-11 |
WO1997007128A1 (en) | 1997-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11511968A (ja) | 抗原提示細胞上にて抗原密度を増加させる方法 | |
JP3836151B2 (ja) | Rnaを添加された抗原提示細胞を用いる癌および病原体感染の治療方法 | |
JP6931598B2 (ja) | Cd4+t細胞応答を向上するための修飾されたエピトープ | |
Gurunathan et al. | DNA vaccines: immunology, application, and optimization | |
RU2709711C2 (ru) | Новые иммуногенные пептиды | |
Walden et al. | Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes. | |
US7994146B2 (en) | Method of enhancing an immune response | |
Ahlers et al. | Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines | |
Yamaguchi et al. | Teleost cytotoxic T cells | |
JP2002515868A (ja) | Hla結合ペプチド及びその使用 | |
JP2008214360A (ja) | ストレスタンパク質を含む組成物を使用する免疫応答 | |
CN110536898B (zh) | 用于治疗糖尿病的肽及方法 | |
JP2005535627A (ja) | アジュバント不含ペプチド・ワクチン | |
Hermans et al. | Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge | |
AU660278B2 (en) | Enhancing the association of exogenous peptides with class 1 MHC molecules on immune system cells | |
US20040223977A1 (en) | Fusion peptide HIV vaccines | |
JP2008531530A (ja) | Hivエピトープ及び同じものを含む製薬組成物 | |
Zanetti et al. | B lymphocytes as antigen‐presenting cell‐based genetic vaccines | |
CA2274837A1 (en) | Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene | |
WO1995028958A1 (en) | Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant | |
Murashev et al. | Immunogenicity of candidate DNA vaccine based on subtype A of human immunodeficiency virus type 1 predominant in Russia | |
CA3226957A1 (en) | Methods for developing cd3+cd8+ cells against multiple viral epitopes for treatment of viral infections including variants evolving to escape previous immunity | |
Alimonti | Utilizing the transporter associated with antigen processing (tap) to enhance immune responsiveness to cancers and viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060912 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071204 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080508 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080617 |